Published in final edited form as:

J Biol Rhythms. 2014 August ; 29(4): 277–287. doi:10.1177/0748730414544740.

The hepatic circadian clock modulates xenobiotic metabolism in mice

Jason P DeBruyne^{1,2}, David R Weaver^{1,*}, and Robert Dallmann^{1,3,*}

¹Department of Neurobiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA ³Institute for Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland

Abstract

The circadian clock generates daily cycles of gene expression that regulate physiological processes. The liver plays an important role in xenobiotic metabolism, and also has been shown to possess its own cell-based clock. The liver clock is synchronized by the master clock in the brain, and a portion of rhythmic gene expression can be driven by behavior of the organism as a whole even when the hepatic clock is suppressed. So far, however, there is relatively little evidence indicating whether the liver clock is functionally important in modulating xenobiotic metabolism. Thus, mice lacking circadian clock function in the whole body or specifically in liver were challenged with pentobarbital and acetaminophen, and pentobarbital sleep time (PBST) and acetaminophen toxicity, respectively, was assessed at different times of day in mutant and control mice. The results suggest that the liver clock is essential for rhythmic changes in xenobiotic detoxification. Surprisingly, it seems that the way in which the clock is disrupted determines the rate of xenobiotic metabolism in the liver. CLOCK-deficient mice are remarkably resistant to acetaminophen and exhibit a longer PBST, while PERIOD-deficient mice have a short PBST. These results indicate an essential role of the tissue-intrinsic peripheral circadian oscillator in the liver in regulating xenobiotic metabolism.

Keywords

Clock; xenobiotic metabolism; mouse; acetaminophen; circadian rhythms; pentobarbital; cytochrome P450; *Bmal1*; *Period*

Introduction

The efficacy and toxicity of many drugs vary with time of day. These time-dependent effects could be due to differences in pharmacokinetics (absorption, distribution, metabolism, or excretion) or pharmacodynamics (rhythms in cellular sensitivity) (Dallmann et al. 2014).

*Address for correspondence: Robert Dallmann, dallmann@pharma.uzh.ch or David R. Weaver, david.weaver@umassmed.edu.

²Present Address for J.P.D.: Neuroscience Institute and Department of Pharmacology, Morehouse School of Medicine, Atlanta, GA.

A network of circadian oscillators exists throughout the body (Mohawk et al. 2012; Weaver and Emery 2013). The suprachiasmatic nuclei (SCN) of the hypothalamus contain the pacemaker controlling behavioral and physiological rhythms. The SCN receive information about the day/night cycle from the retina and thus are synchronized to the environment. The SCN act as a transducer, generating a variety of behavioral, physiological and hormonal rhythms which entrain cell-autonomous circadian clocks in peripheral tissues (Mohawk et al. 2012).

The molecular circadian oscillator is a transcriptional-translational feedback loop that oscillates with a cycle length of approximately 24 hours. At the core of the oscillator are the bHLH/PAS domain-containing transcription factors, CLOCK and BMAL1. These proteins heterodimerize and enhance transcription through E-box elements in regulatory regions of responsive genes. Among their targets are the *Period* (*Per1-3*) and *Cryptochrome* (*Cry1-2*) genes, whose protein products feed back to inhibit CLOCK:BMAL1 activity. Numerous transcription factors are rhythmically regulated in parallel, secondarily establishing rhythmicity in their target genes. Assessment of gene expression rhythms in several tissues reveal that ~10% of all genes and proteins are expressed with 24-hour rhythmicity, with key, rate-limiting steps often among the rhythmic genes (Koike et al. 2012; Akhtar et al. 2002; Storch et al. 2002; Panda et al. 2002; Mauvoisin et al. 2014).

The three PAR-domain containing, basic leucine zipper (PARbZip) transcription factors, D-site binding protein (DBP), thyrotroph embryonic factor (TEF) and hepatic leukemia factor (HLF) are rhythmically expressed in liver under direct control of the CLOCK:BMAL1 complex (Ripperger and Schibler 2006). Mice lacking these three genes have a greatly reduced capability to metabolize xenobiotics due to their activating function upon cytochrome P450 oxidoreductase (POR) (Gachon et al. 2006). These genes and their rhythmically expressed target genes thus link the molecular circadian oscillator to time-of-day dependence of xenobiotic metabolism.

The hierarchical nature of the circadian timing system raises the question of the relative importance of SCN-driven, systemic influences versus local, tissue-intrinsic processes in generating functional rhythmicity. Several studies indicate that cell-autonomous circadian oscillations present in peripheral tissues have physiologically important roles (Storch et al. 2007; Sadacca et al. 2011; Marcheva et al. 2010), while other work indicates that SCN-driven rhythmicity can impose molecular rhythmicity on peripheral tissues in which the molecular oscillator is disrupted (Kornmann et al. 2007; DeBruyne et al. 2007b; Hughes et al. 2012).

To assess the functional importance of the hepatic circadian oscillator in xenobiotic metabolism, we investigated the response of wild-type and circadian mutant mice to two xenobiotic agents, pentobarbital (PB) and N-acetyl-para-aminophenol (APAP, also known as acetaminophen and paracetamol). Both PB and APAP have time-of-day dependent effects (Scheving et al. 1968; Sato et al. 2005; Xu et al. 2012; Kim and Lee 1998; Kakan et al. 2011) and are metabolized exclusively by the cytochrome P450 (CYP) system of the liver (Henderson et al. 2006; Henderson et al. 2003). APAP is of significant interest because this widely used analgesic is the leading cause of drug-induced acute liver failure in the United

States (Larson et al. 2005). Toxicity results from metabolism of APAP, generating N-acetyl-p-benzoquinone imine (NAPQI). CYP2E1 and CYP1A2 are major cytochromes responsible for APAP metabolism, and disruption of these genes blocks APAP metabolism and results in resistance to APAP toxicity (Zaher et al. 1998). CYP2E1 mRNA and protein are rhythmic in rat liver (Khemawoot et al. 2007), suggesting a molecular mechanism for rhythmicity in APAP toxicity.

Several mouse models are available for investigating the impact of disrupted circadian clock function on physiology. CLOCK-deficient mice have only modest alterations in locomotor activity rhythms, revealing redundancy between CLOCK and NPAS2 in the SCN (DeBruyne et al. 2007a; Dallmann et al. 2011). Peripheral tissues from these mice are arrhythmic when examined *ex vivo* (DeBruyne et al. 2007b). Mice homozygous for a conditional allele of *Clock* allow tissue-specific circadian clock disruption. Peripheral tissues of mice deficient in CLOCK or BMAL1 lack positive drive to the circadian oscillator, while mice without PER1, PER2, and PER3 (*Per123^{-/-}*) lack negative feedback. Both, the *Bmal1^{-/-}* and *Per123^{-/-}* mice lack central and peripheral circadian rhythmicity.

Using mice with disruption of the circadian clock genes introduced above, we show here that the liver clock can be essential for time-of-day dependent changes in xenobiotic detoxification. Our results further suggest that the manner in which the circadian clock is disrupted determines whether xenobiotic detoxification remains at high or low levels. These results reveal the functional importance of the liver clock.

Materials and Methods

Animals

All experimental animals were generated and maintained in a specific pathogen-free facility at the University of Massachusetts Medical School, Worcester. All experiments involving animals were approved by the Institutional Animal Care and Use Committee at the University of Massachusetts Medical School, Worcester, MA, and were conducted in accordance with international and National Institute of Health guidelines.

Albumin-Cre mice were purchased from Jackson Labs (Bar Harbor, ME, stock # 003574) (Postic et al. 1999). Founder PER2::LUCIFERASE mice (Yoo et al. 2004) were generously provided by Dr. Joseph S. Takahashi (University of Texas Southwestern Medical Center, Dallas TX). Founder *Bmal1^{+/-}* mice (Bunger et al. 2000) were generously provided by Dr. Christopher A. Bradfield (University of Wisconsin, Madison). Mice with a null allele of *Clock* (resulting from deletion of exons 5 and 6), and mice in which these exons were conditional (flanked by *loxP*) have been previously reported (DeBruyne *et al.*, 2006) and were obtained from our colony. These lines have all been backcrossed to C57BL/6J for at least 9 generations.

Mice with targeted disruption of *Per1*, *Per2*, and *Per3* on the Sv129 genetic background have been previously described (Bae et al. 2001; Shearman et al. 2000b). Triple-mutant (*Per123^{-/-}*) mice were obtained from our colony. Congenic wild-type Sv129 mice were used as controls.

Study animals were genotyped by PCR amplification of genomic DNA extracted from tail biopsies. Products were separated by agarose gel electrophoresis and visualized with ethidium bromide. Primers and PCR conditions have been previously described: for the three *Per* genes (Bae et al. 2001; Shearman et al. 2000a), *Clock* and *Per2::Luc* (DeBruyne et al. 2006), *Bmal1* (Bunger et al., 2000), and *Alb-Cre* (Etcregaray et al. 2009).

For all xenobiotic assays, we used adult (3-8 month old) male mice. *Bmal1*^{-/-} and *Clock*^{-/-} mice were compared with their wild-type littermate controls. *Alb-Cre*⁺; *Clock*^{flx/flx} mice were compared to *Clock*^{flx/flx} littermate controls. For PER2::LUCIFERASE recordings, *Alb-Cre*⁺; *Clock*^{flx/flx}; *Per2*^{luc/+} mice were compared to littermate controls lacking the *Alb-Cre* transgene (*Clock*^{flx/flx}; *Per2*^{luc/+}).

Unless otherwise noted, animals were housed in cages with food and acidified water available *ad libitum*, and maintained in climate controlled closets at 21 ± 1 °C and 45 % humidity with 12 hours of light per day (LD 12:12). During the light phase of the lighting cycle, white light was emitted from fluorescent bulbs (ca. 100 lux). Dim red light (> 600 nm) was present at all times.

Pentobarbital sleep-time assay (PBST)

For the sleep time assay, pentobarbital sodium salt (Sigma, St. Louis, MO, USA) dissolved in sterile saline was injected intraperitoneally (i.p.) at a dose of 40 or 50 mg/kg body weight as indicated for each experiment. Unless otherwise noted, animals were fasted 12 hours before injection by placing them in a fresh cage with an empty food hopper, but with water available at all times. Immediately after injection, animals were returned to their home cage until they lost consciousness. Then, they were gently placed on their back. “Sleep time” was calculated as time from injection to regaining of the righting reflex, i.e., the time at which the animal was able to right itself 3 times within one minute (modified after: Dandiya and Cullumbine 1959). All injections were made on the first day of constant darkness (DD) at indicated times with the exception of the experiment to examine the influence of previous food availability shown in Fig. 2, in which mice were tested on the first and second day in DD. Food removal occurred during darkness, less than 24 hours after the last light-to-dark transition. Mice were fasted for 12 or 24 hr before testing at CT2 or were fasted for 24 or 36 hours before testing at CT14 (see Supplemental Fig. S1A & S1B).

Pentobarbital measurement

Twelve hours after food removal, PB (50 mg/kg) was injected into wild-typed mice on the first day of DD (at CT14 or at CT2). Animals were randomly split into two groups. In one group of mice, blood samples were obtained 30 min after injection. In the second group, blood samples were obtained at the time the animals regained the righting reflex. Blood samples were collected by decapitation, were allowed to clot on ice for > 20 minutes. Samples were centrifuged, and serum was obtained and frozen at -20°C. PB levels in serum were assayed by HPLC at the Core Laboratory of the University of Massachusetts Memorial Hospital (Worcester, MA).

Acetaminophen (APAP) toxicity

APAP toxicity was assessed by measuring alanine amino-transferase (ALT) activity in serum 24 hours after APAP injection on the first day in constant darkness at the indicated times (see paradigm in Supplemental Fig. S1C). For these experiments, APAP (Sigma-Aldrich) was dissolved in pre-warmed sterile saline and injected i.p. at a dose of 250 mg/kg unless otherwise noted. In each experiment, two animals were injected with sterile saline only as controls. In all cases, these control values were comparable to ALT levels in saline injected mice from the literature (< 100 IU/l) and thus, are only reported once in the results section. To assess the impact of different doses of APAP, mice ($n = 3$ per group) were injected i.p. with saline or with APAP at 100, 250, 400 or 600 mg/kg.

After injection with APAP, animals were returned to their home cage for 24 hours. Then, animals were decapitated and blood was collected from the trunk. After clotting, serum was collected, and ALT levels analyzed in duplicate with a colorimetric end point measurement kit scaled from the manufacturer's protocol (Teco Diagnostics, Anaheim, CA).

Data analysis

All data are given as mean $\pm$ standard error of the mean (SEM). Data were compared using 1- or 2-way ANOVA with factors CT (time) and genotype and Bonferroni's *post-hoc* test if appropriate. All statistical tests were 2-tailed and the level of significance was set to $\alpha = 0.05$.

Results

Circadian rhythmicity in PBST is due to hepatic PB metabolism

Previous studies reported diurnal changes in PBST, measured with a lighting cycle present (Davis 1962; Sato et al. 2005; Scheving et al. 1968). Because the ambient lighting condition could influence PBST ("masking"), we first assessed whether PBST is rhythmic in constant darkness, i.e., whether PBST is under circadian control. Groups of wild-type mice injected with PB differed significantly depending on circadian time (1-way ANOVA, $p < 0.001$). We observed a strong, nearly 2-fold circadian variation in PBST with peak sleep times at CT2 (125.8 ± 7.1 min) and shortest sleep times at CT14 (68 ± 6.0 min). Intermediate values were observed at CT8 (88.0 ± 2.1 min) and CT20 (88.6 ± 5.3 min, Fig. 1).

Prior food intake is known to influence PBST in mice (Lovell 1986), which is why we removed food from all animals 12 hours before assessing PBST. Due to rhythmicity in food intake, however, these groups likely differed in the food consumed prior to removing their food. To assess whether this could contribute to the rhythm in PBST, animals were fasted for 12, 24, or 36 hours before administration of PB. PBST differed between CT2 and CT14 irrespective of the duration of prior fasting. PBST was only dependent on the circadian time of PB injection (1-way ANOVA, $p = 0.001$, Fig. 2).

Pentobarbital acts mainly through GABA_A-receptors in the brain (Rudolph and Antkowiak 2004), which show daily variation in their abundance (Chassard and Bruguerolle 2004). Thus, rhythmicity in PBST could be caused by rhythmicity in the rate of hepatic PB

metabolism, by rhythmicity in the hypnotic effects of a given concentration of PB, or by a combination of these mechanisms. To address this, we assessed PB levels in serum in one group of mice 30 minutes after injection (before the animals regained the righting reflex), and assessed PB levels in another group of mice upon regaining the righting reflex (“awakening”). At 30 minutes after injection, levels of PB in serum were significantly higher in mice injected at CT2 than in those injected at CT14 ($p < 0.05$; Fig. 3), suggesting a more rapid clearance of PB at CT14. When assayed at the time the animals regained the righting reflex, serum PB levels did not differ between mice injected at CT2 and CT14 ($p = 0.49$). Thus, rhythmicity in PBST appears to be primarily due to rhythmicity in hepatic metabolism rather than to rhythmicity in the hypnotic effects of PB. Although pharmacodynamic effects based on for example receptor availability cannot be excluded from our data, this interpretation is further substantiated by the results obtained in the liver-specific CLOCK deficient mice (see below).

Circadian rhythmicity in APAP toxicity

Previous publications indicate that peak APAP toxicity in rodents occurs at the time of the maximal rate of metabolism of APAP, early in the night-time (Kim and Lee 1998; Matsunaga et al. 2004). Our results with PBST indicate that the highest rate of PB metabolism occurs early in the subjective night (CT14). Thus, for examining APAP toxicity, we focused our efforts on the expected peak and trough times, CT14 and CT2, respectively. In wild-type mice, injection of APAP (250 mg/kg, i.p.) at CT2 was well-tolerated and led to only slight elevation in ALT levels compared to saline injected control mice. In contrast, ALT levels were greatly elevated following injection of the same APAP dose at CT14 (Fig. 4).

We attempted to rule out the impact of food intake preceding the APAP injection because shifting food intake into the day has been shown to impact on APAP toxicity (Matsunaga et al. 2004), by removing food 12 hours prior to APAP injection (as in the PBST experiments). Fasting for 12 hours prior to APAP injection at CT2 induced high levels of toxicity, which were not reversed by a 1-hour re-feeding opportunity (Supplemental Fig. S2). The increased toxicity following fasting could be due to induction of CYP2E1 by fasting (Leclercq et al. 2000). Irrespective of the mechanism, this experiment indicates that fasting has pronounced effects on APAP toxicity and thus fasting cannot be used to probe the potential impact of prior food intake on APAP toxicity.

Rhythms in PBST are absent in mice with disrupted circadian clocks

In contrast to wild-type controls with an intact circadian clockwork, disruption of the molecular clock led to a loss of the rhythm in PBST (Fig. 5). CLOCK-deficient mice maintain locomotor activity rhythms in constant darkness (DeBruyne et al. 2006). Despite disruption of their molecular clockwork in peripheral tissues (as revealed by loss of rhythmicity in liver and lung explants recorded *ex vivo* (DeBruyne et al. 2007b), there is moderate imposed rhythmicity on liver proteins and gene expression *in vivo*, with no apparent change in phase (DeBruyne et al. 2006). We thus expected that *Clock*^{-/-} mice would show rhythmic PBST. Surprisingly, PBST in *Clock*^{-/-} mice did not differ between CT2 and CT14 (108 ± 8 min vs. 98 ± 5 min, respectively, $p > 0.05$). The CLOCK-deficient

mice had sleep times at both CT2 and CT14 that were comparable to that of wild-type controls at CT2 (108 ± 7 min), but were more than twice that of wild-type mice at CT14 (45 ± 4 min, Fig. 5).

Similarly, disruption of the positive drive within the molecular clock in a different mouse line, i.e., the arrhythmic *Bmal1*^{-/-} mouse, disrupted the PBST rhythm in the same way: there was no difference in PBST between *Bmal1*^{-/-} mice injected at CT2 (66 ± 5 min) and CT14 (52 ± 8 min). As with CLOCK-deficient mice, *Bmal1*^{-/-} mice had long sleep times at both time tested comparable to control mice injected with PB at CT2 (Fig. 5).

In contrast, ablation of the negative limb of the feedback loop (i.e., in mice with disruption of all three *Period* genes) “clamped” the PBST at low values similar to those of strain-matched wild-type mice at CT14 (Fig. 5). PBST of *Per123*^{-/-} mice was not different between CT2 (30 ± 1 min) and CT14 (26 ± 1 min). Thus, *Clock*^{-/-}, *Bmal1*^{-/-} and *Per123*^{-/-} lack rhythmicity in PBST, but they differ in whether they resembled controls injected at CT2 (*Clock*^{-/-}, *Bmal1*^{-/-}) or at CT14 (*Per123*^{-/-}).

APAP toxicity is reduced and is not rhythmic in CLOCK-deficient mice

Clock^{-/-} mice tolerated APAP treatment remarkably well at both times of day examined (Fig. 6A). Even more unexpectedly, *Clock*^{-/-} mice were relatively resistant to APAP across a range of doses up to 600 mg/kg, even when studied at CT14 (the time at which wild-type controls were maximally sensitive) (Fig. 6B).

To further examine the resistance of *Clock*^{-/-} mice to APAP toxicity, we examined their response to APAP after fasting for 12 hours. As noted above, fasting increased APAP toxicity in wild-type mice even at the low-toxicity time (CT2) (Fig. 6C, Supplemental Fig. S2). In contrast, APAP toxicity remained low in fasted *Clock*^{-/-} mice at both times examined (Fig. 6C).

Rhythms in PBST and APAP toxicity are absent in mice lacking CLOCK only in the liver

We generated mice in which CLOCK expression was disrupted specifically in the liver, by intercrossing mice with the widely used *Albumin-Cre* driver with mice bearing conditional alleles of *Clock*. As expected, mice with liver-specific disruption of *Clock* (*Alb-Cre*;⁺ *Clock*^{flox/flox}) lacked CLOCK protein in the liver, and lacked circadian reporter gene oscillations in explants of liver, while normal rhythms were present in lung explants (Supplemental Fig. S3)

In their response to both PBST and APAP, the *Alb-Cre*;⁺ *Clock*^{flox/flox} mice were similar to mice lacking CLOCK throughout the body. PBST of *Alb-Cre*;⁺ *Clock*^{flox/flox} mice at CT2 (129 ± 8 min) and at CT14 (119 ± 8 min) did not differ (Bonferroni's *post-hoc* test, $p > 0.05$), and both were comparable to sleep times of *Clock*^{flox/flox} control mice at CT2 (129 ± 11 min), which was significantly longer than control *Clock*^{flox/flox} mice at CT14 (62 ± 2 min; Bonferroni's *post-hoc* test, $p < 0.001$; Fig. 7A). Similarly, liver toxicity following APAP treatment of *Alb-Cre*;⁺ *Clock*^{flox/flox} mice was low at both CT2 and CT14 (Fig. 7B), as in *Clock*^{-/-} mice. Thus, in both assays, mice lacking *Clock* (either throughout the body, or specifically in the liver), responded to these two xenobiotics administered at either CT2 or

CT14 in a manner similar in magnitude to wild-type mice receiving comparable treatments at CT2. Thus, the increase in hepatic xenobiotic metabolism that normally occurs at CT14 in WT mice is absent in mice lacking hepatic CLOCK.

Discussion and conclusions

The circadian system is an important modulator of metabolism in general (Dallmann et al. 2012; Eckel-Mahan et al. 2012) and xenobiotic metabolism in particular (Gachon et al. 2006; Dallmann et al. 2014). How the circadian clock controls metabolism is less clear. For example, systemic cues can generate rhythms in expression of a subset of hepatic genes even when the hepatic circadian clock is crippled (Kornmann et al. 2007; DeBruyne et al. 2006). Conversely, disruption of food intake greatly reduced rhythmic gene expression even in a genetically intact liver clock (Vollmers et al. 2009). This poses the question of whether the cell-autonomous clock in the liver is essential to generate rhythmicity in xenobiotic metabolism.

Here, we used two xenobiotic agents metabolized by the liver to show that the liver clock is essential for rhythmic xenobiotic metabolism of the whole organism. The lines of evidence indicating the importance of the tissue-autonomous hepatic clock in rhythmic xenobiotic metabolism are (1) hepatic metabolism (rather than neuronal sensitivity) is responsible for circadian differences in PBST (Fig. 3), and (2) rhythmicity in PBST and APAP toxicity is lost in mice in which the circadian clock was selectively disrupted in liver, using *Alb-Cre* +; *Clock^{flox/flox}* mice (Fig. 7). These findings extend previous work indicating rhythmicity in barbiturate sleep time and APAP toxicity (Xu et al. 2012; Dai et al. 2006; Matsunaga et al. 2004; Kim and Lee 1998; Arthur et al. 2003; Scheving et al. 1968; Sato et al. 2005; Gachon et al. 2006). While others have speculated “that dosing time dependent hypnotic durations might be explained by differing sensitivity of the CNS (pharmacodynamics) rather than pharmacokinetics” (Sato et al. 2005) our work demonstrates that the circadian clock *within the liver* is necessary for this rhythmicity, strongly arguing that this effect is predominantly pharmacokinetic in nature.

In wild-type mice, PBST was shorter and APAP-induced toxicity was greater at CT14, compared to CT2. It is important to keep in mind that APAP toxicity is due to its conversion to the toxic metabolite, NAPQI, and more rapid metabolism of APAP to NAPQI is associated with more severe hepatotoxicity (Kim and Lee 1998; Zaher et al. 1998). Our results are thus consistent in showing increased xenobiotic metabolism in the liver of wild-type mice at CT14.

Mice lacking CLOCK or BMAL1 lack rhythmicity in PBST and APAP toxicity (Figs. 5-7), and are similar to WT mice at CT2 in both assays, apparently being unable to increase xenobiotic metabolism above this basal level. Conversely, mice lacking all 3 *Per* gene products behave like WT mice at CT14 in the PBST assay, whether injected with PB at CT2 or CT14 (Fig. 5). Our APAP studies were limited to two time-points, so we cannot completely exclude the possibility that rhythms in APAP toxicity persist with altered phase in the mutant mice, but this seems very unlikely based on the comparable phase in peak

clock gene and protein expression previously reported in CLOCK-deficient mice (DeBruyne et al. 2006) and the absence of rhythmicity in mice lacking the three *Per* genes or BMAL1.

The pattern of results indicates that the differences in xenobiotic metabolism among these mutant lines are direct effects of a malfunctioning circadian clock, as opposed to representing pleiotropic, clock-independent effects. Breaking the clock by disabling the CLOCK:BMAL1 activator complex stops the transcriptional feedback loop in the opposite phase compared with breaking the clock by disabling the PER/CRY repressor complex. In our studies, CLOCK or BMAL1 deficiency has the opposite effect compared to disruption of the *Per* genes, consistent with a role for these complexes, and the circadian oscillator as a whole, in activating and repressing xenobiotic metabolism, respectively. In this respect, our data are in line with greatly reduced and arrhythmic CYP dependent detoxification capacity in mice lacking *Dbp/Hlf/Tef* genes due to low levels of hepatic POR expression (Gachon et al. 2006). CLOCK:BMAL1 complexes act as direct transcriptional activators of the *Dbp/Hlf/Tef* genes. While other rhythmically regulated genes also likely contribute to rhythmic metabolism of xenobiotics, the remarkable resistance of CLOCK-deficient mice to high APAP doses (Fig. 6B), and their resistance to fasting-induced enhancement of APAP toxicity (Fig. 6C) suggest that the circadian transcriptional activator complex is a very important ‘modulator’ of xenobiotic metabolism. This is further substantiated by published data for hepatic POR expression in mice lacking BMAL1 specifically in liver, in which POR expression is clamped at minimal levels throughout the circadian cycle (Lamia et al. 2008). To underscore the magnitude of this modulation, note that *Clock*^{-/-} mice are as well-protected from APAP toxicity as CYP2E1-deficient mice (Lee et al. 1996) and mice with liver-specific POR deletion (Henderson et al. 2003); CYP2E1 and POR are the major enzymes responsible for APAP’s hepatotoxicity.

As noted above, it is useful to compare the effect of breaking the circadian clock by disabling the transcriptional activator complex with breaking the clock by disabling the repressor complex. Our results are consistent with a role for these complexes in activating and repressing xenobiotic metabolism, respectively. This pattern of modulation implicates the circadian clock, rather than pleiotropic functions of the affected genes. A similar pattern of results is seen for the contribution of circadian clock genes to wound healing (Kowalska et al. 2013), and regulation of NAD⁺ and glucose (Ramsey and Bass, 2007). Circadian clock function has also been implicated by studies indicating that disruption of clock function by any methods leads to a *similar* phenotype or pathology (Cheng et al., 2011; reviewed in Yu and Weaver 2011), although in these cases the mechanisms are less clear. In other studies, disrupting the circadian clock in “opposite” ways leads to phenotypes which differ and are not obviously opposite, for example in neurodegeneration (Musiek et al. 2013), making it more difficult to identify the role of the circadian clock separately from other actions of circadian clock proteins. In contrast, in our study, the clock-controlled *Dbp/Hlf/Tef* genes likely provide a direct link between the circadian clock and xenobiotic metabolism.

Small molecule modulators have been described that act on peripheral and central clocks through various molecular targets (Chen et al. 2012; Solt et al. 2012; Yamaguchi et al. 2013; Hirota et al. 2012). It seems likely that development of “chronobiotic” compounds with biological activity *in vivo* may provide a novel mechanism to rapidly adjust the hepatic

circadian clock to a favorable molecular time, leading to a favorable profile of genes involved in xenobiotic metabolism. This may afford a new approach to reducing APAP-induced toxicity. As noted above, disruption of CLOCK:BMAL1 activity is one approach. Another approach is suggested by our finding that disruption of the three *Per* genes leads to short PBST, suggestive of rapid xenobiotic metabolism. Conversely, enhancing activity within the negative limb of the feedback loop may reduce xenobiotic metabolism. PER and CRYPTOCHROME (CRY) proteins work together to produce negative feedback. Small molecule compounds that can stabilize CRY proteins have been described recently (Hirota et al. 2012). Compounds with similar activity and biological activity *in vivo* could augment the negative feedback effect within the circadian clockwork, altering output gene expression rhythms to reduce xenobiotic metabolism. CRY1 is an especially interesting target because it also appears to be involved in the rhythmic modulation of CYP2E1 expression through inhibition of hepatic nuclear factor-1 α (HNF-1 α) (Matsunaga et al. 2008). In addition, this work suggests the possibility that single nucleotide polymorphisms and other genetic variations in circadian clock genes may also contribute to inter-individual differences in xenobiotic metabolism, as has been shown for other metabolic functions (Garcia-Rios et al. 2012).

Recently, it has been suggested that one possible mechanism of action of APAP is dependent on electrophilic metabolites, generated by CYPs expressed in the spinal cord, acting on TRPA1 (Andersson et al. 2011). Our data indicating circadian rhythmicity of APAP metabolism (as assessed by hepatotoxicity) suggest that the rate of production of these electrophilic metabolites may also be time-of-day dependent. If this is the case, both therapeutic (analgesic) and side effects (hepatotoxicity) of APAP may be influenced by time of day.

In summary, the hepatic circadian clock plays an important role in modulating xenobiotic metabolism. The hepatic circadian clock contributes to enhancing metabolism of PB and APAP early in the night-time. Disruption of the liver clock by disrupting genes involved in the circadian transcriptional activator complex (CLOCK or BMAL1) leads to consistently low xenobiotic metabolism, while disruption of the feedback repressive complex (e.g., *Per* genes) leads to persistence of elevated xenobiotic metabolism. These findings suggest novel mechanisms by which xenobiotic detoxification can be manipulated, possibly preventing liver damage by APAP, chemotherapeutics, or other xenobiotics.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank Christopher Lambert for technical assistance, Drs. J.S. Takahashi and C.A. Bradfield for providing mouse lines, S.M. Reppert for encouragement during early phases of this project, and Michael Arand for comments on a previous version of the manuscript. This work was supported by the National Institutes of Health (R21 NS051458 and R01 NS056125 to DRW, and NRSA F32 GM074277 to JPD), and the Deutsche Forschungsgemeinschaft (DA525/2-1 to RD) and Alexander von Humboldt Foundation (3.3-DEU/1131488 FLF to RD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the sponsoring agencies.

List of abbreviations

ALT	alanine amino-transferase
ANOVA	analysis of variance
APAP	N-acetyl-para-aminophenol (acetaminophen; paracetamol)
CT	Circadian Time
CYP P450	cytochrome P450
LD	light/dark cycle
NAPQI	N-acetyl-p-benzoquinone imine
PB	pentobarbital
PBST	pentobarbital sleep time
SCN	suprachiasmatic nuclei
ZT	Zeitgeber Time

References

- Akhtar RA, Reddy AB, Maywood ES, Clayton JD, King VM, Smith AG, Gant TW, Hastings MH, Kyriacou CP. Circadian cycling of the mouse liver transcriptome, as revealed by cDNA microarray, is driven by the suprachiasmatic nucleus. *Curr Biol.* 2002; 12:540–550. [PubMed: 11937022]
- Andersson DA, Gentry C, Alenmyr L, Killander D, Lewis SE, Andersson A, Bucher B, Galzi JL, Sterner O, Bevan S, Hogestatt ED, Zygmunt PM. TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid Delta(9)-tetrahydrocannabinol. *Nat Communications.* 2011; 2:551. doi:10.1038/ncomms1559.
- Arthur KA, Kuehn LA, Hohenboken WD. Sleep time following anesthesia in mouse lines selected for resistance or susceptibility to fescue toxicosis. *J Anim Sci.* 2003; 81:2562–2567. [PubMed: 14552384]
- Bae K, Jin X, Maywood ES, Hastings MH, Reppert SM, Weaver DR. Differential functions of *mPer1*, *mPer2*, and *mPer3* in the SCN circadian clock. *Neuron.* 2001; 30:525–536. [PubMed: 11395012]
- Bunger MK, Wilsbacher LD, Moran SM, Clendenin C, Radcliffe LA, Hogenesch JB, Simon MC, Takahashi JS, Bradfield CA. *Mop3* is an essential component of the master circadian pacemaker in mammals. *Cell.* 2000; 103:1009–1017. [PubMed: 11163178]
- Chassard D, Bruguerolle B. Chronobiology and anesthesia. *Anesthesiology.* 2004; 100:413–427. [PubMed: 14739819]
- Chen Z, Yoo SH, Park YS, Kim KH, Wei S, Buhr E, Ye ZY, Pan HL, Takahashi JS. Identification of diverse modulators of central and peripheral circadian clocks by high-throughput chemical screening. *Proc Natl Acad Sci U S A.* 2012; 109:101–106. doi:10.1073/pnas.1118034108. [PubMed: 22184224]
- Cheng B, Anea CB, Yao L, Chen F, Patel V, Merloiu A, Pati P, Caldwell RW, Fulton DJ, Rudic RD. Tissue-intrinsic dysfunction of circadian clock confers transplant arteriosclerosis. *Proc Natl Acad Sci U S A.* 2011; 108:17147–17152. doi: 10.1073/pnas.1112998108. [PubMed: 21969583]
- Dai G, He L, Chou N, Wan YJ. Acetaminophen metabolism does not contribute to gender difference in its hepatotoxicity in mouse. *Toxicol Sci.* 2006; 92:33–41. [PubMed: 16611625]
- Dallmann R, Brown SA, Gachon F. Chronopharmacology: new insights and therapeutic implications. *Ann Rev Pharm Tox.* 2014; 54:339–361. doi:10.1146/annurevpharmtox-011613-135923.
- Dallmann R, DeBruyne JP, Weaver DR. Photic resetting and entrainment in CLOCK-deficient mice. *J Biol Rhythms.* 2011; 26:390–401. [PubMed: 21921293]

- Dallmann R, Viola AU, Tarokh L, Cajochen C, Brown SA. The human circadian metabolome. *Proc Natl Acad Sci U S A*. 2012; 109:2625–2629. [PubMed: 22308371]
- Dandiya PC, Cullumbine H. Studies on *Acorus calamus* (III); some pharmacological actions of the volatile oil. *J Pharmacol Exp Ther*. 1959; 125:353–359. [PubMed: 13642279]
- Davis WM. Day-night periodicity in pentobarbital response of mice and the influence of socio-psychological conditions. *Experientia*. 1962; 18:235–237. [PubMed: 13883977]
- DeBruyne JP, Noton E, Lambert CM, Maywood ES, Weaver DR, Reppert SM. A clock shock: mouse CLOCK is not required for circadian oscillator function. *Neuron*. 2006; 50:465–477. [PubMed: 16675400]
- DeBruyne JP, Weaver DR, Reppert SM. CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock. *Nat Neurosci*. 2007a; 10:543–545. [PubMed: 17417633]
- DeBruyne JP, Weaver DR, Reppert SM. Peripheral circadian oscillators require CLOCK. *Curr Biol*. 2007b; 17:R538–539. [PubMed: 17637349]
- Eckel-Mahan KL, Patel VR, Mohny RP, Vignola KS, Baldi P, Sassone-Corsi P. Coordination of the transcriptome and metabolome by the circadian clock. *Proc Natl Acad Sci U S A*. 2012; 109:5541–5546. doi:10.1073/pnas.1118726109. [PubMed: 22431615]
- Etchegaray JP, Machida KK, Noton E, Constance CM, Dallmann R, Di Napoli MN, DeBruyne JP, Lambert CM, Yu EA, Reppert SM, Weaver DR. Casein kinase 1 delta regulates the pace of the mammalian circadian clock. *Mol Cell Biol*. 2009; 29:3853–3866. [PubMed: 19414593]
- Gachon F, Olela FF, Schaad O, Descombes P, Schibler U. The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. *Cell Metab*. 2006; 4:25–36. [PubMed: 16814730]
- Garcia-Rios A, Perez-Martinez P, Delgado-Lista J, Phillips CM, Gjelstad IMF, Wright JW, Karlstrom B, Kie'c-Wilk B, van Hees AMJ, Helal O, Polus A, Defoort C, Riserus U, Blaak EE, Lovegrove JA, Drevon CA, Roche HM, Lopez-Miranda J. A Period 2 genetic variant interacts with plasma SFA to modify plasma lipid concentrations in adults with metabolic syndrome. *J Nutrition*. 2012; 142:1213–1218. doi:DOI 10.3945/jn.111.156968. [PubMed: 22623394]
- Henderson CJ, Otto DM, Carrie D, Magnuson MA, McLaren AW, Rosewell I, Wolf CR. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. *J Biol Chem*. 2003; 278:13480–13486. [PubMed: 12566435]
- Henderson CJ, Pass GJ, Wolf CR. The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity. *Toxicology Letters*. 2006; 162:111–117. [PubMed: 16343823]
- Hirota T, Lee JW, St John PC, Sawa M, Iwaisako K, Noguchi T, Pongsawakul PY, Sonntag T, Welsh DK, Brenner DA, Doyle FJ 3rd, Schultz PG, Kay SA. Identification of small molecule activators of cryptochrome. *Science*. 2012; 337:1094–1097. doi:10.1126/science.1223710. [PubMed: 22798407]
- Hughes ME, Hong HK, Chong JL, Indacochea AA, Lee SS, Han M, Takahashi JS, Hogenesch JB. Brain-specific rescue of Clock reveals system-driven transcriptional rhythms in peripheral tissue. *PLoS Genetics*. 2012; 8:e1002835. doi:10.1371/journal.pgen.1002835. [PubMed: 22844252]
- Kakan X, Chen P, Zhang JF. Clock gene mPer2 functions in diurnal variation of acetaminophen induced hepatotoxicity in mice. *Exp Tox Pathol*. 2011; 63:581–585. doi:DOI 10.1016/j.etp.2010.04.011.
- Khemawoot P, Nishino K, Ishizaki J, Yokogawa K, Miyamoto K. Circadian rhythm of cytochrome P4502E1 and its effect on disposition kinetics of chlorzoxazone in rats. *Eur J Pharmacol*. 2007; 574:71–76. [PubMed: 17651723]
- Kim YC, Lee SJ. Temporal variation in hepatotoxicity and metabolism of acetaminophen in mice. *Toxicology*. 1998; 128:53–61. [PubMed: 9704905]
- Koike N, Yoo SH, Huang HC, Kumar V, Lee C, Kim TK, Takahashi JS. Transcriptional architecture and chromatin landscape of the core circadian clock in mammals. *Science*. 2012; 338:349–354. doi:10.1126/science.1226339. [PubMed: 22936566]
- Kornmann B, Schaad O, Bujard H, Takahashi JS, Schibler U. System-driven and oscillator-dependent circadian transcription in mice with a conditionally active liver clock. *PLoS Biol*. 2007; 5:e34. [PubMed: 17298173]

- Kowalska E, Ripperger JA, Hoegger DC, Bruegger P, Buch T, Birchler T, Mueller A, Albrecht U, Contaldo C, Brown SA. N₂O couples the circadian clock to the cell cycle. *Proc Natl Acad Sci U S A*. 2013; 110:1592–1599. [PubMed: 23267082]
- Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, Reisch JS, Schiodt FV, Ostapowicz G, Shakil AO, Lee WM. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. *Hepatology* (Baltimore, MD). 2005; 42:1364–1372.
- Leclercq IA, Field J, Enriquez A, Farrell GC, Robertson GR. Constitutive and inducible expression of hepatic CYP2E1 in leptin-deficient ob/ob mice. *Biochem Biophys Res Commun*. 2000; 268:337–344. [PubMed: 10679205]
- Lee SS, Buters JT, Pineau T, Fernandez-Salguero P, Gonzalez FJ. Role of CYP2E1 in the hepatotoxicity of acetaminophen. *J Biol Chem*. 1996; 271:12063–12067. [PubMed: 8662637]
- Lovell DP. Variation in pentobarbitone sleeping time in mice. 2. Variables affecting test results. *Lab Anim*. 1986; 20:91–96. [PubMed: 3702329]
- Marcheva B, Ramsey KM, Buhr ED, Kobayashi Y, Su H, Ko CH, Ivanova G, Omura C, Mo S, Vitaterna MH, Lopez JP, Philipson LH, Bradfield CA, Crosby SD, JeBailey L, Wang X, Takahashi JS, Bass J. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. *Nature*. 2010; 466:627–631. [PubMed: 20562852]
- Matsunaga N, Ikeda M, Takiguchi T, Koyanagi S, Ohdo S. The molecular mechanism regulating 24-hour rhythm of CYP2E1 expression in the mouse liver. *Hepatology* (Baltimore, MD). 2008; 48:240–251. doi:10.1002/hep.22304.
- Matsunaga N, Nakamura N, Yoneda N, Qin T, Terazono H, To H, Higuchi S, Ohdo S. Influence of feeding schedule on 24-h rhythm of hepatotoxicity induced by acetaminophen in mice. *J Pharmacol Exp Ther*. 2004; 311:594–600. [PubMed: 15205452]
- Mauvoisin D, Wang J, Jouffe C, Martin E, Atger F, Waridel P, Quadroni M, Gachon F, Naef F. Circadian clock-dependent and -independent rhythmic proteomes implement distinct diurnal functions in mouse liver. *Proc Natl Acad Sci U S A*. 2014; 111:167–172. doi:10.1073/pnas.1314066111. [PubMed: 24344304]
- Mohawk JA, Green CB, Takahashi JS. Central and peripheral circadian clocks in mammals. *Ann Rev Neurosci*. 2012; 35:445–462. doi:10.1146/annurev-neuro-060909-153128. [PubMed: 22483041]
- Musiek ES, Lim MM, Yang G, Bauer AQ, Qi L, Lee Y, Roh JH, Ortiz-Gonzalez X, Dearborn JT, Culver JP, Herzog ED, Hogenesch JB, Wozniak DF, Dikranian K, Giasson BI, Weaver DR, Holtzman DM, Fitzgerald GA. Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. *J Clin Invest*. 2013; 123:5389–5400. [PubMed: 24270424]
- Panda S, Antoch MP, Miller BH, Su AI, Schook AB, Straume M, Schultz PG, Kay SA, Takahashi JS, Hogenesch JB. Coordinated transcription of key pathways in the mouse by the circadian clock. *Cell*. 2002; 109:307–320. [PubMed: 12015981]
- Postic C, Shiota M, Niswender KD, Jetton TL, Chen YJ, Moates JM, Shelton KD, Lindner J, Cherrington AD, Magnuson MA. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. *J Biol Chem*. 1999; 274:305–315. doi:DOI 10.1074/jbc.274.1.305. [PubMed: 9867845]
- Ripperger JA, Schibler U. Rhythmic CLOCK-BMAL1 binding to multiple E-box motifs drives circadian Dbp transcription and chromatin transitions. *Nat Genet*. 2006; 38:369–374. [PubMed: 16474407]
- Rudolph U, Antkowiak B. Molecular and neuronal substrates for general anaesthetics. *Nat Rev Neurosci*. 2004; 5:709–720. [PubMed: 15322529]
- Sadacca LA, Lamia KA, deLemos AS, Blum B, Weitz CJ. An intrinsic circadian clock of the pancreas is required for normal insulin release and glucose homeostasis in mice. *Diabetologia*. 2011; 54:120–124. doi:10.1007/s00125-010-1920-8. [PubMed: 20890745]
- Sato Y, Seo N, Kobayashi E. The dosing-time dependent effects of intravenous hypnotics in mice. *Anesthesia Analgesia*. 2005; 101:1706–1708. [PubMed: 16301245]
- Scheving LE, Vedral DF, Pauly JE. A circadian susceptibility rhythm in rats to pentobarbital sodium. *Anat Rec*. 1968; 160:741–749. [PubMed: 5666663]
- Shearman LP, Jin X, Lee C, Reppert SM, Weaver DR. Targeted disruption of the mPer3 gene: Subtle effects on circadian clock function. *Mol Cell Biol*. 2000a; 20:6269–6275. [PubMed: 10938103]

- Shearman LP, Sriram S, Weaver DR, Maywood ES, Chaves I, Zheng B, Kume K, Lee CC, van der Horst GT, Hastings MH, Reppert SM. Interacting molecular loops in the mammalian circadian clock. *Science*. 2000b; 288:1013–1019. [PubMed: 10807566]
- Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, Shin Y, Liu J, Cameron MD, Noel R, Yoo SH, Takahashi JS, Butler AA, Kamenecka TM, Burris TP. Regulation of circadian behaviour and metabolism by synthetic REVERB agonists. *Nature*. 2012; 485:62–68. doi:10.1038/nature11030. [PubMed: 22460951]
- Storch KF, Lipan O, Leykin I, Viswanathan N, Davis FC, Wong WH, Weitz CJ. Extensive and divergent circadian gene expression in liver and heart. *Nature*. 2002; 417:78–83. [PubMed: 11967526]
- Storch KF, Paz C, Signorovitch J, Raviola E, Pawlyk B, Li T, Weitz CJ. Intrinsic circadian clock of the mammalian retina: importance for retinal processing of visual information. *Cell*. 2007; 130:730–741. [PubMed: 17719549]
- Vollmers C, Gill S, DiTacchio L, Pulivarthy SR, Le HD, Panda S. Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression. *Proc Natl Acad Sci U S A*. 2009; 106:21453–21458. [PubMed: 19940241]
- Weaver, DR.; Emery, P. Circadian Timekeeping. In: Squire, LR.; Berg, D.; Bloom, FE.; du Lac, S.; Ghosh, A.; Spitzer, NC., editors. *Fundamental Neuroscience*. 4th ed. Academic Press; Oxford: 2013. p. 819-845.
- Xu YQ, Zhang D, Jin T, Cai DJ, Wu Q, Lu Y, Liu J, Klaassen CD. Diurnal variation of hepatic antioxidant gene expression in mice. *PLoS One*. 2012; 7:e44237. [PubMed: 22952936]
- Yamaguchi Y, Suzuki T, Mizoro Y, Kori H, Okada K, Chen Y, Fustin JM, Yamazaki F, Mizuguchi N, Zhang J, Dong X, Tsujimoto G, Okuno Y, Doi M, Okamura H. Mice genetically deficient in vasopressin V1a and V1b receptors are resistant to jet lag. *Science*. 2013; 342:85–90. doi:10.1126/science.1238599. [PubMed: 24092737]
- Yoo S-H, Yamazaki S, Lowrey PL, Shimomura K, Ko CH, Buhr ED, Slepka SM, Hong H-K, Oh WJ, Yoo OJ, Menaker M, Takahashi JS. PERIOD2::LUCIFERASE real-time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues. *Proc Natl Acad Sci U S A*. 2004; 101:5339–5346. [PubMed: 14963227]
- Yu EA, Weaver DR. Disrupting the circadian clock: gene-specific effects on aging, cancer, and other phenotypes. *Aging*. 2011; 3:479–93. [PubMed: 21566258]
- Zaher H, Buters JT, Ward JM, Bruno MK, Lucas AM, Stern ST, Cohen SD, Gonzalez FJ. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. *Toxicology and applied pharmacology*. 1998; 152:193–199. [PubMed: 9772215]

Figure 1. PBST is time-of-day dependent in wild-type mice

Relative pentobarbital sleep time (PBST) of wild-type mice injected i.p. with 50 mg/kg PB at indicated circadian times ($n = 4-5$ per group) as percent of PBST at CT2 ($100\% \triangleq 125.8 \pm 7.1$ min). Statistically significant differences vs. CT2 in Bonferroni's *post hoc* test are given as *** $p < 0.001$. Open bars = subjective day (CT2, 8), filled bars = subjective night (CT14, 20).

Figure 2. PBST is not dependent on duration of prior fasting

The influence of fasting on PBST in B6 mice was tested by i.p. injecting 40 mg/kg PB at CT2 or CT14 with prior fasting of 12, 24, or 36 hours. (See Supplemental Figure S1B). PBST was determined for $n = 5$ animals per group. Values are given as relative PBST (percent of average PBST after 12 hours of fasting at CT2 (control, $100\% \pm 60.4 \pm 2.8$ min). Statistically significant differences in Bonferroni's *post-hoc* test indicated as * $p < 0.05$, n.s. not significant.

Figure 3. PB clearance from serum is dependent on time of day

PB (40 mg/kg i.p.) was injected at CT2 or CT14 in wild-type mice ($n = 5-7$ per group), and PB concentration in serum was measured 30 minutes after injection (left), or (in a second independent groups of animals) after the mice regained their righting reflex (“awake”, right). In *post-hoc* testing of 2-way ANOVA, PB levels at 30 minutes after injection differed significantly between CTs (*, $p = 0.01$, Bonferroni’s t -test), but not at the time of recovery from anesthesia (n.s., $p = 0.49$).

Figure 4.

Effect of i.p. saline (Saline, n = 2 per group) or 250 mg/kg acetaminophen (APAP, n = 6 per group) injection at two circadian times in wild-type animals. Statistically significant differences vs. CT2 in Bonferroni's *post hoc* test are given as ** p < 0.01. Black bars = saline controls, open bars = subjective day (CT2), filled bars = subjective night (CT14).

Figure 5. Rhythm in PBST is disrupted in mice with whole-body disruption of circadian clock genes

PBST in *Clock*^{-/-} (n = 6 per group, left, diagonally hatched), *Bmal1*^{-/-} (n = 4-5 per group, middle, horizontally hatched) and *Per123*^{-/-} (n = 6 per group, right, dotted) compared to their respective control wild-type mice after injection of 50 mg/kg PB. In order to facilitate easy comparison between experiments, PBST is normalized to CT2 of the wild-type control value for each experiment (100% values of controls at CT2: *Clock*-WT 107.6 ± 7.3 min, *Bmal1*-WT 62.8 ± 6.4 min, *Per123*-WT 50.2 ± 5.4 min). Statistical differences in Bonferroni's *post-hoc* test between CTs are indicated as n.s. not significant, ** p < 0.01 or *** p < 0.001. Open bars = subjective day (CT2), filled bars = subjective night (CT14).

Figure 6. *Clock*^{-/-} mice are resistant to APAP toxicity

(A) ALT levels in wild-type and *Clock*^{-/-} (hatched) mice following APAP (250 mg/kg) administration at CT2 or CT14 (n=5 per group). (B) Dose range experiment with indicated doses of APAP in wild-type (closed circles) and *Clock*^{-/-} (open squares) mice at CT 14 (n = 3 per group). (C) Twelve hours of food deprivation before APAP (250 mg/kg) injection increases APAP toxicity in wild-type but not in *Clock*^{-/-} (hatched) mice at CT2 and CT14 (note the difference in values between Panel A and Panel C). Statistically significant differences between genotypes in Bonferroni's *post-hoc* test after 2-way ANOVA are indicated as n.s. not significant, * $p < 0.05$, *** $p < 0.001$.

Figure 7. Rhythms in PBST and APAP toxicity are absent in liver-specific CLOCK deficient mice

(A) PBST in *Alb-Cre-;Clock^{flx/flx}* mice (Cre-) and *Alb-Cre+;Clock^{flx/flx}* mice (Cre+, hatched) ($n = 6$ per group) after 50 mg/kg PB injection. PBST is normalized to CT2 of the wild-type control value ($100\% \triangleq 128.7 \pm 11.0$ min). (B) APAP toxicity measured by ALT levels in *Alb-Cre-;Clock^{flx/flx}* mice (Cre-) and *Alb-Cre+;Clock^{flx/flx}* mice (Cre+) ($n = 6$ per group) after injection of 250 mg/kg APAP. Results of Bonferroni's *post-hoc* comparison of CTs within each genotype are given as n.s. not significant and *** $p < 0.001$.